Life, changing.
More than 600,000 cancer patients worldwide have used our Oncotype DX tests to personalise treatments and improve outcomes.
Our Mission
Genomic Health’s mission is to transform treatment decisions and outcomes in cancer by delivering clinically actionable diagnostics and services.

Making An Impact

Genomic Health is leading in the precision medicine revolution to eliminate the "one-size-fits-all" approach to cancer treatment.
Predicting Cancer Outcomes
Oncotype DX leads industry as only test proven to predict chemotherapy benefit and with prospective clinical outcomes data in more than 50,000 breast cancer patients worldwide.
"The Oncotype DX test gives you the peace of mind and the reassurance that the treatment plan that you and your doctor have decided upon is the right one."

Coree H.

Broadening Access for Patients Worldwide
Genomic Health is dedicated to securing access to ensure cancer patients around the world have access to our clinically actionable Oncotype DX tests. Outside the U.S., there are over 195 million lives covered and growing. The Oncotype DX prostate cancer test is now covered by Medicare in the U.S. for qualified patients, giving nearly 60,000 prostate cancer patients the opportunity to personalise their cancer treatment.
“I was determined to educate myself about all of my options, and thanks to Oncotype DX, I have not lost any sleep or been worried since I decided to go on active surveillance based on my very low GPS result.”

Dan W.